Literature DB >> 25143442

Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory Fc receptor interactions that reduce target cell availability.

Anthony J Smith1, Stephen W Wietgrefe1, Liang Shang1, Cavan S Reilly2, Peter J Southern1, Katherine E Perkey1, Lijie Duan1, Heinz Kohler3, Sybille Müller4, James Robinson5, John V Carlis6, Qingsheng Li7, R Paul Johnson8, Ashley T Haase9.   

Abstract

Principles to guide design of an effective vaccine against HIV are greatly needed, particularly to protect women in the pandemic's epicenter in Africa. We have been seeking these principles by identifying correlates of the robust protection associated with SIVmac239Δnef vaccination in the SIV-rhesus macaque animal model of HIV-1 transmission to women. We identified one correlate of SIVmac239Δnef protection against vaginal challenge as a resident mucosal system for SIV-gp41 trimer Ab production and neonatal FcR-mediated concentration of these Abs on the path of virus entry to inhibit establishment of infected founder populations at the portal of entry. In this study, we identify blocking CD4(+) T cell recruitment to thereby inhibit local expansion of infected founder populations as a second correlate of protection. Virus-specific immune complex interactions with the inhibitory FcγRIIb receptor in the epithelium lining the cervix initiate expression of genes that block recruitment of target cells to fuel local expansion. Immune complex-FcγRIIb receptor interactions at mucosal frontlines to dampen the innate immune response to vaginal challenge could be a potentially general mechanism for the mucosal immune system to sense and modulate the response to a previously encountered pathogen. Designing vaccines to provide protection without eliciting these transmission-promoting innate responses could contribute to developing an effective HIV-1 vaccine.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25143442      PMCID: PMC4157094          DOI: 10.4049/jimmunol.1400822

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus.

Authors:  Christopher J Miller; Qingsheng Li; Kristina Abel; Eun-Young Kim; Zhong-Min Ma; Stephen Wietgrefe; Lisa La Franco-Scheuch; Lara Compton; Lijie Duan; Marta Dykhuizen Shore; Mary Zupancic; Marc Busch; John Carlis; Steven Wolinsky; Steven Wolinksy; Ashley T Haase
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Live attenuated AIDS vaccines: hazards and hopes.

Authors:  R P Johnson
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Authors:  K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson
Journal:  Virology       Date:  2001-11-10       Impact factor: 3.616

4.  COMMD proteins, a novel family of structural and functional homologs of MURR1.

Authors:  Ezra Burstein; Jamie E Hoberg; Amanda S Wilkinson; Julie M Rumble; Rebecca A Csomos; Christine M Komarck; Gabriel N Maine; John C Wilkinson; Marty W Mayo; Colin S Duckett
Journal:  J Biol Chem       Date:  2005-03-30       Impact factor: 5.157

5.  Poly(C)-binding protein 1 (PCBP1) mediates housekeeping degradation of mitochondrial antiviral signaling (MAVS).

Authors:  Xiang Zhou; Fuping You; Huihui Chen; Zhengfan Jiang
Journal:  Cell Res       Date:  2011-11-22       Impact factor: 25.617

6.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

7.  An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys.

Authors:  S Müller; D H Margolin; G Min
Journal:  Hybridoma       Date:  1997-02

8.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.

Authors:  H Wang; S Müller; S Zolla-Pazner; H Köhler
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

10.  Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Authors:  Bertran Auvert; Dirk Taljaard; Emmanuel Lagarde; Joëlle Sobngwi-Tambekou; Rémi Sitta; Adrian Puren
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069

View more
  22 in total

1.  Vaccine-Associated Maintenance of Epithelial Integrity Correlated With Protection Against Virus Entry.

Authors:  L Shang; A J Smith; L Duan; K E Perkey; S Wietgrefe; M Zupancic; P J Southern; R P Johnson; J V Carlis; A T Haase
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

Review 2.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 3.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

4.  Increases in NKG2C Expression on T Cells and Higher Levels of Circulating CD8+ B Cells Are Associated with Sterilizing Immunity Provided by a Live Attenuated SIV Vaccine.

Authors:  Vida L Hodara; Laura M Parodi; M Shannon Keckler; Luis D Giavedoni
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-17       Impact factor: 2.205

5.  Mucosal Humoral Immune Response to SIVmac239∆nef Vaccination and Vaginal Challenge.

Authors:  Ming Zeng; Anthony J Smith; Liang Shang; Stephen W Wietgrefe; James E Voss; John V Carlis; Qingsheng Li; Michael Piatak; Jeffrey D Lifson; R Paul Johnson; Ashley T Haase
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

6.  Vaccination with Live Attenuated Simian Immunodeficiency Virus (SIV) Protects from Mucosal, but Not Necessarily Intravenous, Challenge with a Minimally Heterologous SIV.

Authors:  Matthew S Sutton; Charles M Burns; Andrea M Weiler; Alexis J Balgeman; Andrew Braasch; Gabrielle Lehrer-Brey; Thomas C Friedrich; Shelby L O'Connor
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

Review 7.  Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.

Authors:  Austin W Boesch; Galit Alter; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

8.  Blocking HIV-1 Infection by Chromosomal Integrative Expression of Human CD4 on the Surface of Lactobacillus acidophilus ATCC 4356.

Authors:  Wenzhong Wei; Joshua Wiggins; Duoyi Hu; Vladimir Vrbanac; Dane Bowder; Michael Mellon; Andrew Tager; Joseph Sodroski; Shi-Hua Xiang
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 9.  Immune correlates of vaccine protection against HIV-1 acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Georgia D Tomaras; Barton F Haynes; Giuseppe Pantaleo; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2015-10-21       Impact factor: 17.956

Review 10.  The COVID-19 Vaccine Landscape.

Authors:  Till Koch; Anahita Fathi; Marylyn M Addo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.